Core Viewpoint - Filinger is expected to report a net loss attributable to shareholders of the parent company ranging from -85 million to -65 million yuan for the year 2025, indicating a continued loss compared to the previous year [1] Group 1: Main Business Impact - The real estate industry remains in an adjustment cycle, with no significant recovery in market demand for the downstream home decoration industry during the reporting period [1] - The company's main business revenue experienced a slight increase compared to the same period last year, but the gross margin declined due to a higher proportion of revenue from lower-margin mid-to-low-end products [1] - The Danyang subsidiary is expected to gradually transition to fixed assets in the second half of 2024, leading to increased depreciation and fixed costs in 2025 [1] - The company plans to make provisions for asset impairment on certain fixed assets and inventory, further exacerbating the losses [1] Group 2: Non-operating Gains and Losses - Non-operating gains and losses are not expected to have a significant impact on the overall financial performance [1]

Core Viewpoint - The company, 聚石化学, is expected to report a negative net profit attributable to shareholders of the parent company for the year 2025, ranging from -1.2 billion to -900 million yuan, with a net profit excluding non-recurring gains and losses projected between -1.55 billion and -1.25 billion yuan [1] Group 1: Performance Changes - The main reasons for the performance changes include the divestment of 冠臻科技, which resulted in receiving some performance compensation and the merger or cancellation of underperforming subsidiaries, thereby reducing operational costs and losses [2] - The modified plastics business is expected to see slight growth in revenue and gross profit in 2025, driven by lower raw material prices in optical display materials, improved capacity and yield, and successful development of the self-owned brand in Nigeria's hygiene products market [2] - The liquefied petroleum gas business is anticipated to experience a significant decline in revenue and increased losses due to fluctuations in international crude oil prices, leading to short-term supply-demand imbalances and price volatility [2] - The fine chemicals business is projected to see revenue growth due to increased demand for polyphosphate, although profits may decrease due to higher fixed costs during the ramp-up phase of the new halogen-free flame retardant production project [2]

Group 1 - The company Xinbo Co., Ltd. expects a net loss attributable to shareholders of 1.38 billion to 1.98 billion yuan for the fiscal year 2025, marking a shift from profit to loss year-on-year [1] - The primary reason for the performance change is the ongoing adjustment phase in the photovoltaic industry, with prices across the entire supply chain remaining under pressure [1] - The company's photovoltaic product processing fees are still on a downward trend, and in the fourth quarter, the company conducted impairment testing on its photovoltaic segment assets, leading to the recognition of asset impairment provisions as required by accounting standards [1] Group 2 - The company's new energy vehicle and recycled aluminum segments are currently in a capacity ramp-up phase, with efficiency and results not meeting expectations [1]

Core Viewpoint - The company, 聚石化学 (688669.SH), is expected to report a negative net profit attributable to shareholders of the parent company for the year 2025, estimated between -1.2 billion to -900 million yuan, with a net profit excluding non-recurring gains and losses projected to be between -1.55 billion to -1.25 billion yuan [1] Group 1: Performance Changes - The main reasons for the performance changes include the divestment of 冠臻科技, which resulted in receiving some performance compensation and the consolidation or deregistration of underperforming subsidiaries, thereby reducing operational costs and losses [2] - The modified plastics business is expected to see slight growth in revenue and gross profit in 2025, driven by lower raw material prices in the optical display materials sector, improved capacity and yield, and successful development of the company's own brand in the Nigerian market [2] - The liquefied petroleum gas business is anticipated to experience a significant decline in revenue and increased losses due to fluctuations in international crude oil prices, leading to short-term supply-demand imbalances and price volatility [2] - The fine chemicals business is projected to see an increase in revenue but a decrease in profit, attributed to rising demand for polyphosphate and the commencement of trial production for a subsidiary's halogen-free flame retardant expansion project, which is currently in a capacity ramp-up phase with higher fixed costs [2]

（记者 王晓波） 每经头条（nbdtoutiao）——水贝黄金平台"杰我睿"兑付危机调查：40倍杠杆对赌，金价越涨平台越 亏！老板自称"还在深圳"，投资者：兑付方案本金打两折，无法接受 每经AI快讯，厦工股份1月29日晚间发布业绩预告，预计公司2025年度实现归属于母公司所有者的净利 润-8700万元到-5800万元，将出现亏损。业绩变动主要原因是，主营业务影响。报告期内，公司盾构机 业务因所在地区工程进度放缓导致营业收入及业务利润同比上年下滑幅度较大，新拓展的智能矿卡业务 尚在爬坡，有待进一步形成规模；报告期内，公司根据客户提供的房产抵押物的评估值下降情况，相应 补计提了应收账款坏账准备，进一步夯实债权资产价值。非经营性损益的影响。本报告期历史呆坏账清 欠回款及一次性收益均少于上年，本期非经营性收益同比下降。 ...

Core Viewpoint - The company, Da Dongfang (600327.SH), is expected to report a significant net loss for the fiscal year 2025, with projections indicating a loss between 235 million to 175 million yuan, compared to the previous year [1] Financial Performance - The anticipated net profit attributable to the parent company for 2025 is projected to be between -235 million yuan and -175 million yuan, indicating a loss compared to the previous year [1] - The expected net profit after deducting non-recurring gains and losses is forecasted to be between -215 million yuan and -155 million yuan [1] Business Segments - The department store business is focusing on enhancing招商力度 (recruitment efforts), strengthening advantageous categories, optimizing consumer scenarios, upgrading customer experience, and enhancing holiday marketing and membership management [1] - Despite efforts in the department store segment, revenue and gross profit have slightly declined due to a downturn in consumer spending and the impact of traditional supermarket channels [1] - The pediatric medical business is concentrating on developing existing business while actively expanding into new disciplines and products, improving the quality of medical services [1] - Although revenue in the pediatric medical segment has decreased, gross profit has increased, leading to a year-on-year profit growth, indicating stable operations in the main business [1]

南财智讯1月29日电，德力股份发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-22,000万元—-17,000万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润 为-19,300万元—-14,300万元。业绩变动原因说明：1、受光伏行业结构性供需矛盾、国际贸易环境等多 重因素的影响，公司全资子公司--蚌埠德力光能材料有限公司虽在报告期初暂时性停炉，但受计提折 旧、资产减值、财务费用及人员薪酬支出等影响，报告期预计亏损近14,500.00万元；2、根据国家相关 部委对清洁能源生产替代的要求，公司对原燃煤窑炉改造为天然气窑炉，报告期内因部分燃煤窑炉炉龄 未到期而发生拆除损失近2,500万元；根据公司产线规划，对闲置固定资产计提减值约800.00万元；3、 报告期内根据公司发展规划，对原药用玻璃项目、北海项目终止，对筹建期发生的支出计提减值约 700.00万元；4、受行业市场竞争加剧的影响，结合以往以及未来市场对日用玻璃器皿需求变化的多样 性，公司对产品的品相、产品结构进行升级调整，对不适用于未来市场需求的长库龄产品进行充分的减 值计提，报告期内按照会计准则规定存货跌价净增加额 ...

Core Viewpoint - The company Shenzhen New Star anticipates a net loss attributable to shareholders of the parent company for the fiscal year 2025, ranging from -69 million to -46 million yuan, indicating a reduction in losses compared to the previous year [1] Financial Performance - The expected net loss represents a decrease in losses by 222.17 million to 245.17 million yuan compared to the same period last year [1] - The net profit after deducting non-recurring gains and losses is projected to be between -73.5 million and -50.5 million yuan [1] - The previous year's net loss attributable to shareholders was -291.17 million yuan [1] Operational Challenges - The anticipated losses are primarily due to the instability in the new production line and the compressed profit margins of lithium hexafluorophosphate products [1]

Core Viewpoint - The company expects a significant annual loss for 2025, projecting a net profit attributable to shareholders between -90 million to -130 million yuan, and a non-recurring net profit between -102 million to -148 million yuan, indicating a strategic transformation struggle [1] Financial Performance - The projected losses contrast sharply with the previous year's net profit of 8.09 million yuan and a non-recurring net profit of -4.11 million yuan [1] - The anticipated losses are attributed to a contraction in traditional IT solution services, leading to decreased revenue and increased costs [1] Strategic Challenges - The company is facing challenges in its innovative business, which has not met profitability expectations [1] - Increased research and development expenditures are contributing to the financial strain [1] - The current year's financial results are also impacted by the accrual of convertible bond interest and stock incentive expenses, which together affect profits by 44.24 million yuan [1]

Group 1 - The core viewpoint of the article indicates that Huiyu Pharmaceutical expects a significant net loss for the fiscal year 2025, projecting a loss between 29 million to 24 million yuan, which represents a year-on-year decline of 108.91% to 107.38% [1] - The primary reason for this performance change is attributed to the fair value loss of 173 million yuan due to fluctuations in the stock price of its invested company, Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd., which is set to be listed on the Hong Kong Stock Exchange on August 20, 2024, under the HKEX 18A listing standard [1]